Laboratory Co. of America Holdings (NYSE:LH) is Cambiar Investors LLC's 5th Largest Position

Cambiar Investors LLC cut its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 2.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 268,450 shares of the medical research company's stock after selling 7,192 shares during the quarter. Laboratory Co. of America accounts for approximately 2.4% of Cambiar Investors LLC's holdings, making the stock its 5th biggest holding. Cambiar Investors LLC owned approximately 0.32% of Laboratory Co. of America worth $61,561,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Mill Creek Capital Advisors LLC purchased a new position in shares of Laboratory Co. of America during the fourth quarter worth approximately $347,000. Kestra Private Wealth Services LLC raised its stake in shares of Laboratory Co. of America by 132.6% during the fourth quarter. Kestra Private Wealth Services LLC now owns 3,056 shares of the medical research company's stock worth $701,000 after acquiring an additional 1,742 shares in the last quarter. Empowered Funds LLC raised its stake in shares of Laboratory Co. of America by 0.5% during the fourth quarter. Empowered Funds LLC now owns 8,025 shares of the medical research company's stock worth $1,840,000 after acquiring an additional 43 shares in the last quarter. Apollon Wealth Management LLC bought a new position in shares of Laboratory Co. of America in the fourth quarter worth approximately $249,000. Finally, Cidel Asset Management Inc. bought a new position in shares of Laboratory Co. of America in the fourth quarter worth approximately $205,000. 95.94% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Laboratory Co. of America

In other news, CEO Adam H. Schechter sold 6,121 shares of Laboratory Co. of America stock in a transaction dated Tuesday, February 11th. The stock was sold at an average price of $244.62, for a total value of $1,497,319.02. Following the completion of the transaction, the chief executive officer now owns 86,445 shares of the company's stock, valued at $21,146,175.90. The trade was a 6.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Amy B. Summy sold 3,672 shares of Laboratory Co. of America stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $238.91, for a total value of $877,277.52. Following the completion of the transaction, the chief marketing officer now directly owns 4,318 shares of the company's stock, valued at approximately $1,031,613.38. This represents a 45.96 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 24,504 shares of company stock valued at $5,905,692 in the last quarter. 0.85% of the stock is owned by insiders.

Laboratory Co. of America Stock Up 0.8 %

Laboratory Co. of America stock traded up $1.87 on Friday, hitting $246.74. 565,887 shares of the stock traded hands, compared to its average volume of 607,910. The company has a current ratio of 1.44, a quick ratio of 1.30 and a debt-to-equity ratio of 0.67. The firm has a market cap of $20.64 billion, a P/E ratio of 27.98, a price-to-earnings-growth ratio of 1.84 and a beta of 1.07. The business's fifty day simple moving average is $237.13 and its 200 day simple moving average is $230.66. Laboratory Co. of America Holdings has a 1 year low of $191.97 and a 1 year high of $258.59.

Laboratory Co. of America (NYSE:LH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $3.45 EPS for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a return on equity of 15.29% and a net margin of 5.73%. As a group, sell-side analysts forecast that Laboratory Co. of America Holdings will post 15.96 earnings per share for the current year.

Laboratory Co. of America Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 12th. Shareholders of record on Thursday, February 27th will be given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.17%. The ex-dividend date is Thursday, February 27th. Laboratory Co. of America's dividend payout ratio is currently 32.65%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. UBS Group cut their target price on shares of Laboratory Co. of America from $293.00 to $286.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Bank of America raised their target price on shares of Laboratory Co. of America from $262.00 to $271.00 and gave the stock a "buy" rating in a report on Friday, December 13th. Robert W. Baird raised their target price on shares of Laboratory Co. of America from $282.00 to $289.00 and gave the stock an "outperform" rating in a report on Friday, October 25th. StockNews.com upgraded shares of Laboratory Co. of America from a "hold" rating to a "buy" rating in a report on Friday, February 7th. Finally, Barclays cut their target price on shares of Laboratory Co. of America from $271.00 to $260.00 and set an "equal weight" rating on the stock in a report on Friday, February 7th. Three investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $265.31.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.